Skip to main content
All lobbying filings

E3 STRATEGIC CONSULTING GROUP

E3 STRATEGIC CONSULTING GROUP filed a Q3 report for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION on October 5, 2026, reporting $60,000 in lobbying income.

Lobbying for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Association

All filings by E3 STRATEGIC CONSULTING GROUP · Everything PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 5, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
Virginia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.

 Bills named in this filing 7
  • S. 1040
    Drug Competition Enhancement Act
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • H.R. 4317
    PBM Reform Act of 2025
  • H.R. 5256
    340B ACCESS Act
  • S. 3345
    PBM Price Transparency and Accountability Act
  • S. 2658
    Medication Affordability and Patent Integrity Act
  • S. 1414
    Expedited Access to Biosimilars Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem